US
CA
NZ
UK
AU
IND
Last update at 2025-06-11T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -98.60100M | -97.48300M | -97.48300M | -115.21200M | -88.33300M |
| Minority interest | 7.89M | 10.91M | 33.27M | 40.35M | 40.97M |
| Net income | -106.13900M | -81.07400M | -81.07400M | -102.09100M | -78.69300M |
| Selling general administrative | 17.49M | 37.87M | 44.20M | 43.02M | 47.25M |
| Selling and marketing expenses | 3.11M | 6.33M | - | 11.43M | 16.68M |
| Gross profit | 17.40M | 37.67M | 37.67M | 3.80M | 9.99M |
| Reconciled depreciation | 18.43M | 16.57M | 9.82M | 6.88M | 2.38M |
| Ebit | -108.10100M | -102.00700M | -95.25600M | -130.42700M | -107.46800M |
| Ebitda | -89.66600M | -85.43700M | -85.43700M | -123.55200M | -105.09100M |
| Depreciation and amortization | 18.43M | 16.57M | 9.82M | 6.88M | 2.38M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | -89.66600M | -85.43700M | -85.43700M | -123.55200M | -105.09100M |
| Other operating expenses | 108.84M | 159.39M | 159.39M | 138.74M | 117.82M |
| Interest expense | 3.79M | 5.34M | 12.05M | 2.61M | 0.05M |
| Tax provision | 0.09M | - | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 1.12M | 0.74M | 1.95M | 6.99M | 6.79M |
| Net interest income | -8.93500M | -4.16100M | -1.31600M | 4.53M | 6.25M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 0.09M | -11.20300M | -24.91200M | -24.52600M | -18.26800M |
| Total revenue | 19.17M | 73.95M | 73.95M | 15.19M | 12.73M |
| Total operating expenses | 107.06M | 123.11M | 123.11M | 127.35M | 115.08M |
| Cost of revenue | 1.77M | 36.27M | 36.27M | 11.39M | 2.74M |
| Total other income expense net | 6.06M | 9.73M | -10.73000M | 3.81M | 10.51M |
| Discontinued operations | -15.34500M | -28.35800M | -43.90200M | -43.90200M | 0.00000M |
| Net income from continuing ops | -98.68800M | -125.10700M | -97.48300M | -115.21200M | -88.33100M |
| Net income applicable to common shares | -106.13900M | -114.19700M | -81.07400M | -102.09100M | -78.69300M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 261.22M | 382.08M | 469.47M | 467.47M | 500.84M |
| Intangible assets | 0.72M | 1.85M | 1.58M | 1.11M | 1.27M |
| Earning assets | - | - | - | - | - |
| Other current assets | 9.08M | 9.66M | 29.64M | 15.62M | 15.33M |
| Total liab | 135.28M | 145.60M | 160.62M | 112.00M | 50.57M |
| Total stockholder equity | 117.97M | 221.29M | 275.57M | 315.12M | 409.30M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 28.52M | 14.60M | 20.26M | 12.24M | 9.90M |
| Common stock | 2.96M | 2.94M | 2.79M | 2.77M | 2.77M |
| Capital stock | 2.96M | 2.94M | 2.79M | 2.77M | 2.77M |
| Retained earnings | -439.50400M | -698.32600M | -587.03500M | -508.48200M | -405.32100M |
| Other liab | 9.35M | 5.96M | 8.63M | 2.85M | 2.68M |
| Good will | - | 0.00100M | -0.00100M | - | 0.00000M |
| Other assets | -0.00100M | 6.52M | 7.01M | 5.52M | 1.89M |
| Cash | 97.70M | 186.13M | 268.24M | 360.91M | 451.89M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 62.99M | 49.35M | 52.02M | 62.60M | 46.87M |
| Current deferred revenue | 0.06M | 0.30M | 0.45M | 20.03M | 20.75M |
| Net debt | -14.84800M | -83.89600M | -156.94300M | -313.30000M | -450.53800M |
| Short term debt | 12.96M | 10.68M | 6.70M | 1.07M | 0.33M |
| Short long term debt | 5.09M | 2.25M | - | 1.07M | 0.33M |
| Short long term debt total | 82.85M | 102.24M | 111.30M | 47.61M | 1.35M |
| Other stockholder equity | 583.12M | 934.70M | 863.91M | 843.48M | 828.52M |
| Property plant equipment | 107.90M | 148.27M | 145.52M | 69.32M | 10.04M |
| Total current assets | 143.81M | 225.43M | 315.36M | 391.52M | 487.64M |
| Long term investments | 8.79M | 6.52M | 7.01M | 5.52M | 1.89M |
| Net tangible assets | 117.25M | 219.44M | 282.21M | 314.01M | 408.03M |
| Short term investments | 7.91M | 0.50M | 27.09M | 20.39M | 0.39M |
| Net receivables | 15.27M | 29.63M | 15.87M | 12.10M | 20.14M |
| Long term debt | 20.53M | 18.77M | 28.84M | 46.54M | 1.02M |
| Inventory | 21.77M | 0.00000M | 1.61M | 2.90M | 0.28M |
| Accounts payable | 21.46M | 23.76M | 24.61M | 29.26M | 15.88M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | -28.60500M | -18.02100M | -4.08900M | -22.64000M | -16.66800M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 0.00100M | 0.00300M | -0.00100M | 75.95M | -0.00100M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 117.41M | 156.65M | 154.11M | 75.95M | 13.20M |
| Capital lease obligations | 57.23M | 79.86M | 82.46M | 47.61M | 1.35M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2.76100M | 27.02M | -8.13600M | -23.32800M | 39.25M |
| Change to liabilities | 3.27M | -0.58300M | -14.11600M | 9.60M | 2.89M |
| Total cashflows from investing activities | -2.76100M | 7.28M | -54.34200M | -35.87200M | 35.62M |
| Net borrowings | -6.60400M | -12.46500M | 17.56M | -3.39300M | -0.12700M |
| Total cash from financing activities | 1.15M | 47.52M | 27.32M | -3.86200M | 236.49M |
| Change to operating activities | -5.80600M | 0.65M | -0.68500M | 7.36M | -8.25700M |
| Net income | -98.68800M | -125.10700M | -97.48300M | -115.21200M | -88.33300M |
| Change in cash | -92.42000M | -55.51200M | -99.37400M | -110.97900M | 195.12M |
| Begin period cash flow | 185.64M | 241.15M | 340.52M | 451.50M | 256.38M |
| End period cash flow | 93.22M | 185.64M | 241.15M | 340.52M | 451.50M |
| Total cash from operating activities | -87.44400M | -104.56200M | -80.26200M | -69.14200M | -68.13700M |
| Issuance of capital stock | - | 48.52M | 9.21M | 0.00000M | 236.62M |
| Depreciation | 18.43M | 16.57M | 9.82M | 6.88M | 2.38M |
| Other cashflows from investing activities | -0.44600M | -0.00100M | -0.00100M | -0.00100M | 0.00100M |
| Dividends paid | 0.00000M | 0.00000M | - | - | 0.00000M |
| Change to inventory | -5.80600M | 1.60M | 1.31M | -2.62700M | -0.03700M |
| Change to account receivables | -3.18700M | -5.83200M | -8.33800M | -2.67400M | -3.69600M |
| Sale purchase of stock | -0.56900M | - | - | -0.46900M | 0.00000M |
| Other cashflows from financing activities | 14.07M | 11.47M | 24.72M | -35.87200M | 35.62M |
| Change to netincome | 5.98M | -2.77200M | 12.82M | 14.42M | 17.27M |
| Capital expenditures | 2.44M | 19.74M | 46.26M | 12.96M | 4.89M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -5.72300M | -4.16300M | -21.82800M | 11.65M | -9.09600M |
| Stock based compensation | 6.04M | 13.12M | 16.74M | 26.88M | 37.22M |
| Other non cash items | -7.59800M | -4.98000M | 12.49M | 0.66M | -10.30300M |
| Free cash flow | -89.88500M | -124.30500M | -126.52200M | -82.10000M | -73.02300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CMVLF Cellectis S.A |
- -% | 1.25 | - | - | 10.45 | 3.37 | 16.85 | -4.9814 |
| NVO Novo Nordisk A/S |
-0.56 0.69% | 80.49 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.41 0.51% | 80.59 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.29 0.28% | 458.77 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.82 0.54% | 524.66 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
8, rue de la Croix Jarry, Paris, France, 75013
| Name | Title | Year Born |
|---|---|---|
| Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director | 1965 |
| Dr. David J. D. Sourdive Ph.D. | Director, Deputy CEO, Exec. VP of CMC and Manufacturing | 1967 |
| Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer | 1977 |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer | NA |
| Mr. Jean Charles Epinat | Chief Technological Officer | NA |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer | 1963 |
| Mr. Stephan Reynier M.Sc., MSc | Chief Regulatory & Pharmaceutical Compliance Officer | 1969 |
| Ms. Marie-Bleuenn Terrier | Gen. Counsel & Sec. of the Board of Directors | 1982 |
| Pascalyne Wilson | Director of Communications | NA |
| Ms. Kyung Nam-Wortman | Exec. VP & Chief HR Officer | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...